Financial Statements

Atara Biotherapeutics, Inc. (ATRA)

$5.16

+0.03 (+0.58%)
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers are in thousands

Retained Earning Schedule

Year 2021 2020 2019 2018 2017
Retained Earnings (Previous Year) -1,125-818-527-297-
Net Income -340-307-291-231-119
Stock Dividends --0--177
Dividend Paid -----
Retained Earnings -1,465-1,125-818-527-297

PPE Schedule

Year 2021 2020 2019 2018 2017
Gross PPE 63686944-
Annual Depreciation 28-156064
Capital Expenditure -11-5-6-36-20
Net PPE 8063686944

Intangible and Goodwill Schedule

Year 2021 2020 2019 2018 2017
Intangible and Goodwill (Previous Year) -----
New Purchases -176-466-270-426-301
Intangible and Goodwill -----

Atara Biotherapeutics, Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Atara Biotherapeutics, Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.